The gut microbiota and host health: a new clinical frontier
By Julian R. Marchesi, D. Adams, F. Fava, Gerben D. A. Hermes, Gideon M. Hirschfield, G. Hold, M. Quraishi, James Kinross, H. Smidt, K. Tuohy and 3 more. Gut, 2015
2,056 citations recorded by the source corpus.
Over the last 10–15 years, our understanding of the composition and functions of the human gut microbiota has increased exponentially. To a large extent, this has been due to new ‘omic’ technologies that have facilitated large-scale analysis of the genetic and metabolic profile of this microbial community, revealing it to be comparable in influence to a new organ in the body and offering the possibility of a new route for therapeutic intervention. Moreover, it might be more accurate to think of it like an immune system: a collection of cells that work in unison with the host and that can promote health but sometimes initiate disease. This review gives an update on the current knowledge in the area of gut disorders, in particular metabolic syndrome and obesity-related disease, liver disease, IBD and colorectal cancer. The potential of manipulating the gut microbiota in these disorders is assessed, with an examination of the latest and most relevant evidence relating to antibiotics, probiotics, prebiotics, polyphenols and faecal microbiota transplantation.
Subfields: Gastroenterology, Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/b80f1c97dd3beac9cc62f434266f1712272beab7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Infectious Diseases
In Molecular Biology
- Patrice D Cani
- Ian A. Wilson
- W. D. de Vos
- Jeremy K. Nicholson
- James Kinross
- Almut Heinken
- G. Svegliati-Baroni
- G. Gibson
Citations in the corpus
- Impact of the gut microbiota on inflammation, obesity, and metabolic disease (2016, background): “In particular, the gut microbiota is believed to contribute to metabolic diseases via stimulation of low-grade inflammation [13].”
- Lipotoxicity and the gut-liver axis in NASH pathogenesis. (2018, background): “Thus faecal microbiota transplantation (FMT) could be considered as a therapeutic options in NAFLD/NASH patients [109].”
- Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila (2017, background): “…improves metabolic disorders associated with obesity, including a decreased fat mass, insulin resistance, lower liver steatosis and a reinforcement of the gut barrier (Figure 1) (Cani et al., 2004, 2006, 2009; Maurer et al., 2010; Everard et al., 2011; Pachikian et al., 2012; Greer et al., 2016).”
- Gut microbiota modulation of chemotherapy efficacy and toxicity (2017, positive): “A major contribution of systems biology to modern medicine has been the rediscovery of the importance of the gut microbiota to almost all aspects of human health 10 .”
- Gut microbiota functions: metabolism of nutrients and other food components (2017, background): “More recently evidence has been accumulating that the microbiota may also be involved in obesity and diabetes [4, 5].”
- The human gut microbiota: Metabolism and perspective in obesity (2018, background): “This change can result in a lowgrade chronic inflammatory process and in metabolic disorders such as those present in obesity.(2) The human gut microbiota consists of up to 100 trillion microbes that exist in a largely symbiotic relationship with their human hosts, carrying at least 150 times more g”